113 Piccadilly Place. Unit A
San Bruno, CA 94066
Altay Therapeutics is developing a novel small molecule inhibitor (ALT-CP4) for fibrosis, which targets a cellular protein that regulates matrix deposition and immune activation. They have developed a novel platform using primary tissues that represents a more clinically relevant heterogeneous cell population. They are generating gene signatures from each active compound which will allows for assaying for broad changes in gene activation in choosing which small molecule to proceed. Their first clinical lead is idiopathic pulmonary fibrosis (IPF).